Research Paper Volume 12, Issue 5 pp 4573—4591

APEX1 is a novel diagnostic and prognostic biomarker for hepatocellular carcinoma


Figure 7. High APEX1 expression correlates with resistance against sorafenib and anti-PD1 immunotherapy in HCC patients. (A, B) APEX1 and AFP mRNA expression in 46 sorafenib-resistant and 21 sorafenib-sensitive HCC patients from the GSE109211 dataset is shown. (C, D) APEX1 and AFP expression in three anti-PD1 immunotherapy-resistant and three anti-PD1 immunotherapy-sensitive HCC patients belonging to the GSE125336 dataset is shown.